Skip to main content

Philips and Paige team up to bring Artificial Intelligence (AI) to clinical pathology diagnostics

Written by Customer Service on . Posted in Public Companies.

December 5, 2019
AI-based  cancer assessment tools are poised to help pathologists improve speed and accuracy of cancer diagnostics, ultimately leading to better patient care
Amsterdam, The Netherlands – Royal Philips ( (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Paige, a leader in computational pathology, announced today a strategic collaboration to deliver clinical-grade AI applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify and characterize cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologist’s workflow and treatment planning for patients.Pathologists play a crucial role in the detection and diagnosis of a broad range of diseases, including cancer. The increasing number of cancer cases in the aging population, and rapid advances in personalized medicine have resulted in significant increases in the complexity of pathology diagnostics and the workload imposed on pathologists. Digital images of tissue samples make it possible for pathologists to easily diagnose these samples on a computer display using advanced imaging analysis and workflow software.Paige’s technology has demonstrated promising results, and the collaboration aims to deliver this kind of technology into routine clinical practice. Several pathology laboratories have already converted their glass slide-based workflow to digital, using the clinically approved digital pathology solution from Philips. Once digital images are available, the CE marked Paige Prostate software is applied automatically to detect and localize prostate cancer. This technology provides pathologists with valuable information they can use in their evaluation of prostate biopsies.“We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer,” said Marlon Thompson, Business Leader of Digital & Computational Pathology at Philips. “Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”“Pathology is transforming into a digital discipline and holds a strong promise for using AI solutions to aid, streamline, and enhance decision-making,” said Leo Grady, CEO of Paige. “Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients.”Philips IntelliSite Pathology Solution in combination with Paige Prostate aims to provide an intuitive digital & computational pathology workflow experience. Philips plans to offer the CE-marked Paige Prostate to European pathology labs in 2020. AI solutions for other markets and additional disease areas are expected to follow suit. Visit www.philips.com/digitalpathology and  https://paige.ai. for more information.For further information, please contact:Joost Maltha
Philips Global Press Office
Tel. : +31 6 10 55 8116
Email: joost.maltha@philips.com  Nicole Rodrigues
NRPR Group – For Paige
Tel.: +1 650 815 5069
Email: nicole@nrprgroup.comAbout Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.About Paige.AI
Paige.AI is the leading start-up focused on building the best artificial intelligence in clinical medicine to transform how doctors diagnose and treat cancer. Based in New York, Paige.AI is bringing together the world’s leading experts in AI, computational pathology and clinical practice to improve patient care through a quantum leap forward in efficacy and efficiency. For more information, please visit: https://paige.ai. AttachmentComputational_Pathology

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.